scholarly journals The GluN2B-Selective Antagonist Ro 25-6981 Is Effective against PTZ-Induced Seizures and Safe for Further Development in Infantile Rats

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1482
Author(s):  
Pavel Mareš ◽  
Lucie Kozlová ◽  
Anna Mikulecká ◽  
Hana Kubová

The GluN2B subunit of NMDA receptors represents a perspective therapeutic target in various CNS pathologies, including epilepsy. Because of its predominant expression in the immature brain, selective GluN2B antagonists are expected to be more effective early in postnatal development. The aim of this study was to identify age-dependent differences in the anticonvulsant activity of the GluN2B-selective antagonist Ro 25-6981 and assess the safety of this drug for the developing brain. Anticonvulsant activity of Ro 25-6981 (1, 3, and 10 mg/kg) was tested in a pentylenetetrazol (PTZ) model in infantile (12-day-old, P12) and juvenile (25-day-old, P25) rats. Ro 25-6981 (1 or 3 mg/kg/day) was administered from P7 till P11 to assess safety for the developing brain. Animals were then tested repeatedly in a battery of behavioral tests focusing on sensorimotor development, cognition, and emotionality till adulthood. Effects of early exposure to Ro 25-6981 on later seizure susceptibility were tested in the PTZ model. Ro 25-6981 was effective against PTZ-induced seizures in infantile rats, specifically suppressing the tonic phase of the generalized tonic–clonic seizures, but it failed in juveniles. Neither sensorimotor development nor cognitive abilities and emotionality were affected by early-life exposure to Ro 25-6981. Treatment cessation did not affect later seizure susceptibility. Our data are in line with the maturational gradient of the GluN2B-subunit of NMDA receptors and demonstrate developmental differences in the anti-seizure activity of the GluN2B-selective antagonist and its safety for the developing brain.

2018 ◽  
Vol 16 (10) ◽  
pp. 1099-1110 ◽  
Author(s):  
Jeffrey M. Witkin ◽  
Douglas A. Schober ◽  
Scott D. Gleason ◽  
John T. Catlow ◽  
Warren J. Porter ◽  
...  

1998 ◽  
Vol 31 ◽  
pp. S342
Author(s):  
Akira Mitani ◽  
Masahiko Watanabe ◽  
Kiyoshi Kataoka

2006 ◽  
Vol 14 (1) ◽  
pp. 49-64 ◽  
Author(s):  
BARBRO B. JOHANSSON

Complex and widespread activation in many brain areas is seen while performing, listening or mentally imaging music, activity that varies with training, previous exposure, personal preference, emotional involvement and many other factors. Playing a musical instrument demands extensive motor and cognitive abilities, and early musical learning results in plastic reorganization of the developing brain – one example being the increased cortical representation area for the left little finger in (right-handed) string-players, which correlates with age at the start of training. Even though the developing brain has the most pronounced changes, the adult healthy brain has a considerable plasticity. Conductors have superior spatial tuning compared with non-musicians and pianists. Attentive listening to music for as little as three hours can temporarily alter the auditory cortex. Interactions between genetic predisposition, environment and training play a role in music as in other areas. It has been proposed that musical training may improve other cognitive functions. There is some evidence that this may be the case but it is an area that needs further exploration.


1978 ◽  
Vol 56 (5) ◽  
pp. 893-896 ◽  
Author(s):  
H. L. Davis ◽  
D. D. Johnson ◽  
R. D. Crawford

Acute dose–response studies were conducted to determine if ethosuximide had anticonvulsant activity against seizures evoked by stroboscopic stimulation of epileptic fowl and to correlate the observed effects with the concentration of the drug in the plasma. Ethosuximide, in doses that produced mean plasma concentrations of 366 μg/ml and signs of sedation, did not reduce seizure susceptibility. Twice daily administration of ethosuximide produced mean plasma concentrations of 430 μg/ml after 36 h without affecting seizure susceptibility even in the presence of marked sedation. Previous studies have shown that epileptic fowl are sensitive to the anticonvulsant effects of phenobarbital, phenytoin, and primidone at plasma concentrations similar to those required in humans. Since ethosuximide has a high specificity against petit mal seizures in humans, the failure of ethosuximide to provide protection indicates that epileptic fowl represent a relatively specific pharmacological model for drugs effective against generalized tonic–clonic and focal cortical epilepsies in humans.


1993 ◽  
Vol 232 (1) ◽  
pp. 59-64 ◽  
Author(s):  
Grażyna Czechowska ◽  
Marek Dziki ◽  
Teresa Pietrasiewicz ◽  
Zdzisław Kleinrok ◽  
Waldemar A. Turski ◽  
...  

2002 ◽  
Vol 70 (5) ◽  
pp. 2147-2155 ◽  
Author(s):  
Vincent Mutel ◽  
Danièle Buchy ◽  
Agnès Klingelschmidt ◽  
Jürg Messer ◽  
Zaiga Bleuel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document